Patisiran, a triweekly intravenously administered TTR‐directed, double‐stranded, small interfering RNA, is approved in the United States for the treatment of the polyneuropathy of hATTR in adults (Alnylam Pharmaceuticals Inc., 2018) and in Europe for the treatment of hATTR in adults with stage 1 or 2 polyneuropathy (Alnylam Netherlands B.V., 2018). The gene discussed is TTR; the disease is polyneuropathy.